読み込み中
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
前日終値
$16.53
+$1.39 · +9.18%
日中の時刻はETです。市場データは遅延する場合があります。
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
日中レンジ
現在 $16.53
52週レンジ
現在 $16.53
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
43
まちまち
リスク
68
高リスク
モメンタム
29
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
日中レンジ
現在 $16.53
52週レンジ
現在 $16.53
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 1779 USD | 3612 USD | 3612 USD | 3612 USD | 3612 USD |
| 粗利益 | −1779 USD | −3612 USD | −3612 USD | −3612 USD | −3612 USD |
| 研究開発 | 1722.04万 USD | 1548.02万 USD | 769.86万 USD | 647.57万 USD | 355.95万 USD |
| 販売・一般管理 | 222.57万 USD | 215.34万 USD | 162.92万 USD | 156.46万 USD | 103.84万 USD |
| 営業費用 | 1944.61万 USD | 1763.36万 USD | 932.43万 USD | 803.66万 USD | 459.43万 USD |
| 受取利息 | 8.97万 USD | 22.3万 USD | 43.61万 USD | 21.5万 USD | 2.74万 USD |
| 減価償却費と償却費 | 1779 USD | 3612 USD | 3612 USD | 3612 USD | 3612 USD |
| 営業利益 | −1944.79万 USD | −1763.72万 USD | −932.79万 USD | −804.03万 USD | −459.79万 USD |
| 純利益 | −1935.82万 USD | −1741.42万 USD | −889.18万 USD | −782.52万 USD | −457.06万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$50.00
上昇余地（202.48%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM309.3万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI297.53万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 Growth ETFIWO108.96万0.01%139.17億 USD0.24%$356.78+0.94%
Vanguard Extended Market ETFVXF108.04万0.00%954億 USD0.05%$235+0.80%
Vanguard U.S. Momentum Factor ETFVFMO80.4万0.04%19億 USD0.13%$230.11+1.02%
Vanguard Russell 2000 ETFVTWO57.75万0.00%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC37.25万0.03%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG11.21万0.01%17億 USD0.06%$260.49+0.91%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
